Inhibitors of the growth factors TGF-β1 and VEGF showed greater inhibitory effects on leiomyoma cell viability than conventional drugs, indicating their potential as therapeutic agents for uterine leiomyoma. This evidence concerns the gene TGFB1 and uterine corpus leiomyoma.